AU651816B2 - Induction of protection against viral infection - Google Patents
Induction of protection against viral infection Download PDFInfo
- Publication number
- AU651816B2 AU651816B2 AU74989/91A AU7498991A AU651816B2 AU 651816 B2 AU651816 B2 AU 651816B2 AU 74989/91 A AU74989/91 A AU 74989/91A AU 7498991 A AU7498991 A AU 7498991A AU 651816 B2 AU651816 B2 AU 651816B2
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- hiv
- virus
- envelope glycoprotein
- host
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000006698 induction Effects 0.000 title claims description 14
- 230000009385 viral infection Effects 0.000 title description 5
- 208000036142 Viral infection Diseases 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 123
- 241000700605 Viruses Species 0.000 claims abstract description 88
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 72
- 101710121417 Envelope glycoprotein Proteins 0.000 claims abstract description 66
- 239000000203 mixture Substances 0.000 claims abstract description 58
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 20
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 10
- 230000010530 Virus Neutralization Effects 0.000 claims abstract description 9
- 102100021696 Syncytin-1 Human genes 0.000 claims abstract 24
- 238000000034 method Methods 0.000 claims description 65
- 239000000427 antigen Substances 0.000 claims description 55
- 108091007433 antigens Proteins 0.000 claims description 55
- 102000036639 antigens Human genes 0.000 claims description 55
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 55
- 208000031886 HIV Infections Diseases 0.000 claims description 47
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 46
- 238000006386 neutralization reaction Methods 0.000 claims description 45
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 44
- 239000002671 adjuvant Substances 0.000 claims description 23
- 230000037452 priming Effects 0.000 claims description 23
- 230000005847 immunogenicity Effects 0.000 claims description 11
- 238000002255 vaccination Methods 0.000 claims description 11
- 230000002708 enhancing effect Effects 0.000 claims description 9
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 7
- 230000036039 immunity Effects 0.000 claims description 5
- 230000005923 long-lasting effect Effects 0.000 claims description 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 3
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 3
- 108010028921 Lipopeptides Proteins 0.000 claims description 3
- 108010016626 Dipeptides Proteins 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 26
- 235000001014 amino acid Nutrition 0.000 abstract description 10
- 150000001413 amino acids Chemical class 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 10
- 239000012634 fragment Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 238000002347 injection Methods 0.000 description 62
- 239000007924 injection Substances 0.000 description 62
- 241000282579 Pan Species 0.000 description 51
- 102100034349 Integrase Human genes 0.000 description 48
- 241001465754 Metazoa Species 0.000 description 47
- 241000282577 Pan troglodytes Species 0.000 description 42
- 230000003053 immunization Effects 0.000 description 42
- 238000002649 immunization Methods 0.000 description 41
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 29
- 230000004044 response Effects 0.000 description 28
- 238000002965 ELISA Methods 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 26
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 229960005486 vaccine Drugs 0.000 description 20
- 241001430294 unidentified retrovirus Species 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 17
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 16
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 208000030507 AIDS Diseases 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- LGGRPYXPOUIMKG-OJICBBQQSA-N (2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-6-amino-2-[[(2S,3R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-methylpentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-N-[(2S)-1-[[(2S)-1-amino-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]pentanediamide Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N2CCC[C@H]2C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CC=C(C=C4)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC6=CC=C(C=C6)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]7CCCN7C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]([C@@H](C)O)N LGGRPYXPOUIMKG-OJICBBQQSA-N 0.000 description 11
- 241000700618 Vaccinia virus Species 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000011081 inoculation Methods 0.000 description 11
- 210000001165 lymph node Anatomy 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 239000000562 conjugate Substances 0.000 description 10
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 230000036436 anti-hiv Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 8
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 8
- -1 IDS Species 0.000 description 6
- 108010038807 Oligopeptides Proteins 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 6
- 101710201961 Virion infectivity factor Proteins 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000012809 post-inoculation Methods 0.000 description 6
- 230000002459 sustained effect Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 229940037003 alum Drugs 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 239000007927 intramuscular injection Substances 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000019802 Sexually transmitted disease Diseases 0.000 description 4
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229910018626 Al(OH) Inorganic materials 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 229940033330 HIV vaccine Drugs 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000011436 cob Substances 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- UGXDVELKRYZPDM-XLXQKPBQSA-N (4r)-4-[[(2s,3r)-2-[[(2r)-2-[(2r,3r,4r,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxypropanoyl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O UGXDVELKRYZPDM-XLXQKPBQSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 108700010908 HIV-1 proteins Proteins 0.000 description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- XUGUHTGSMPZQIW-UHFFFAOYSA-N [[4-(4-diazonioiminocyclohexa-2,5-dien-1-ylidene)cyclohexa-2,5-dien-1-ylidene]hydrazinylidene]azanide Chemical compound C1=CC(N=[N+]=[N-])=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 XUGUHTGSMPZQIW-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 101150088264 pol gene Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960000380 propiolactone Drugs 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 108700004027 tat Genes Proteins 0.000 description 2
- 101150098170 tat gene Proteins 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- YUJSWFZLUCHGFO-UHFFFAOYSA-N 4-(4-azidophenyl)aniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(N=[N+]=[N-])C=C1 YUJSWFZLUCHGFO-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 206010000807 Acute HIV infection Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 101100508406 Caenorhabditis elegans ifa-1 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 101710130332 ETS domain-containing protein Elk-4 Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 208000007521 HIV Seropositivity Diseases 0.000 description 1
- 229940033332 HIV-1 vaccine Drugs 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241001136003 Human T-lymphotropic virus 3 Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101710138742 Receptor-type tyrosine-protein phosphatase H Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102400000830 Saposin-B Human genes 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 101100398653 Yersinia pestis lamB1 gene Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 101150012518 lamB gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 108010034897 lentil lectin Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 229960004319 trichloroacetic acid Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49474990A | 1990-03-19 | 1990-03-19 | |
US494749 | 1990-03-19 | ||
PCT/EP1991/000509 WO1991014449A1 (fr) | 1990-03-19 | 1991-03-16 | Induction de protection contre les infections virales |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU64615/94A Division AU6461594A (en) | 1990-03-19 | 1994-06-09 | Induction of protection against viral infection |
Publications (2)
Publication Number | Publication Date |
---|---|
AU7498991A AU7498991A (en) | 1991-10-21 |
AU651816B2 true AU651816B2 (en) | 1994-08-04 |
Family
ID=23965805
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU74989/91A Ceased AU651816B2 (en) | 1990-03-19 | 1991-03-16 | Induction of protection against viral infection |
AU64615/94A Abandoned AU6461594A (en) | 1990-03-19 | 1994-06-09 | Induction of protection against viral infection |
AU71960/98A Abandoned AU7196098A (en) | 1990-03-19 | 1998-06-16 | Induction of protection against viral infection |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU64615/94A Abandoned AU6461594A (en) | 1990-03-19 | 1994-06-09 | Induction of protection against viral infection |
AU71960/98A Abandoned AU7196098A (en) | 1990-03-19 | 1998-06-16 | Induction of protection against viral infection |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0742229A3 (fr) |
JP (2) | JPH03271233A (fr) |
AT (1) | ATE154244T1 (fr) |
AU (3) | AU651816B2 (fr) |
CA (1) | CA2057040A1 (fr) |
DE (1) | DE69126486T2 (fr) |
DK (1) | DK0472706T3 (fr) |
ES (1) | ES2104695T3 (fr) |
GR (1) | GR3024670T3 (fr) |
WO (1) | WO1991014449A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976541A (en) * | 1988-01-26 | 1999-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope |
US5876724A (en) * | 1990-03-19 | 1999-03-02 | Institut Pasteur | Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein |
US6139843A (en) * | 1991-04-02 | 2000-10-31 | Albert Einstein College Of Medicine Of Yeshiva University | Peptide compositions for the treatment of HIV |
DE69233271T2 (de) * | 1991-04-02 | 2004-09-09 | Albert Einstein College Of Medicine Of Yeshiva University | Therapeutischer- und präventivimpfstoff gegen hiv |
JPH07501052A (ja) * | 1991-10-28 | 1995-02-02 | インスティチュート・パスツール | ウイルスエンベロープタンパク質と糖タンパク質の中和エピトープに相当するペプチドとの間の相乗作用によるウイルス感染に対する防御の誘発 |
FR2692898B1 (fr) * | 1992-06-30 | 1995-06-02 | Centre Nat Rech Scient | Procédé d'obtention de protéines membranaires, et utilisation de ces protéines dans un but de diagnostic ou de vaccination. |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0227169A2 (fr) * | 1985-12-17 | 1987-07-01 | Akzo N.V. | Réactif immunochimique |
EP0317804A2 (fr) * | 1987-11-24 | 1989-05-31 | Abbott Laboratories | Peptides de VIH et méthodes de détection de VIH |
EP0326109A2 (fr) * | 1988-01-29 | 1989-08-02 | New York Blood Center, Inc. | Immunogènes contenant des peptides avec une queue hydrophobique attachée pour adsorption à l'antigène de surface de l'hépatite B |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ221440A (en) * | 1986-08-20 | 1991-11-26 | Genetic Systems Corp | Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections |
CA1341285C (fr) * | 1988-02-12 | 2001-08-14 | Chang Yi Wang | Peptides synthetiques servant a la detection d'anticorps de la proteine de surface gp120 du virus hiv, destines au diagnostic du sida, ainsi que d'etats pre-sidatiques, ou aux fins de vaccins |
FR2650954B1 (fr) * | 1989-08-18 | 1992-02-28 | Pasteur Institut | Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida |
-
1990
- 1990-11-30 JP JP2341189A patent/JPH03271233A/ja active Pending
-
1991
- 1991-03-16 EP EP96106172A patent/EP0742229A3/fr not_active Withdrawn
- 1991-03-16 ES ES91906386T patent/ES2104695T3/es not_active Expired - Lifetime
- 1991-03-16 WO PCT/EP1991/000509 patent/WO1991014449A1/fr active IP Right Grant
- 1991-03-16 AU AU74989/91A patent/AU651816B2/en not_active Ceased
- 1991-03-16 DK DK91906386.7T patent/DK0472706T3/da active
- 1991-03-16 CA CA002057040A patent/CA2057040A1/fr not_active Abandoned
- 1991-03-16 AT AT91906386T patent/ATE154244T1/de not_active IP Right Cessation
- 1991-03-16 DE DE69126486T patent/DE69126486T2/de not_active Expired - Fee Related
- 1991-03-16 EP EP91906386A patent/EP0472706B1/fr not_active Expired - Lifetime
- 1991-03-16 JP JP3506292A patent/JPH04506220A/ja active Pending
-
1994
- 1994-06-09 AU AU64615/94A patent/AU6461594A/en not_active Abandoned
-
1997
- 1997-09-10 GR GR970402313T patent/GR3024670T3/el unknown
-
1998
- 1998-06-16 AU AU71960/98A patent/AU7196098A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0227169A2 (fr) * | 1985-12-17 | 1987-07-01 | Akzo N.V. | Réactif immunochimique |
EP0317804A2 (fr) * | 1987-11-24 | 1989-05-31 | Abbott Laboratories | Peptides de VIH et méthodes de détection de VIH |
EP0326109A2 (fr) * | 1988-01-29 | 1989-08-02 | New York Blood Center, Inc. | Immunogènes contenant des peptides avec une queue hydrophobique attachée pour adsorption à l'antigène de surface de l'hépatite B |
Also Published As
Publication number | Publication date |
---|---|
WO1991014449A1 (fr) | 1991-10-03 |
EP0742229A3 (fr) | 1998-06-03 |
EP0472706A1 (fr) | 1992-03-04 |
ATE154244T1 (de) | 1997-06-15 |
EP0472706B1 (fr) | 1997-06-11 |
EP0742229A2 (fr) | 1996-11-13 |
JPH04506220A (ja) | 1992-10-29 |
AU7196098A (en) | 1998-08-13 |
GR3024670T3 (en) | 1997-12-31 |
CA2057040A1 (fr) | 1991-09-20 |
DE69126486T2 (de) | 1998-01-15 |
ES2104695T3 (es) | 1997-10-16 |
AU7498991A (en) | 1991-10-21 |
DE69126486D1 (de) | 1997-07-17 |
AU6461594A (en) | 1994-09-08 |
DK0472706T3 (da) | 1997-12-29 |
JPH03271233A (ja) | 1991-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Girard et al. | Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. | |
Girard et al. | Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1 | |
JP6165612B2 (ja) | コンセンサス/先祖免疫原 | |
Cease et al. | Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. | |
US7993651B2 (en) | Chimeric human immunodeficiency virus (HIV) immunogens comprising GAG P24-P17 fused to multiple cytotoxic T lymphocyte (CTL) epitopes | |
McLain et al. | Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus | |
JP2006020635A (ja) | 抗原的に標識した非感染性レトロウィルス様粒子 | |
KR20070041765A (ko) | Hiv-감염의 예방 및 치료를 위한 백신 | |
PUTKONEN et al. | Vaccine protection against HIV-2 infection in cynomolgus monkeys | |
SK287382B6 (sk) | Očkovacia kompozícia | |
Mills et al. | HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1. | |
Notka et al. | Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies | |
US5876724A (en) | Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein | |
AU651816B2 (en) | Induction of protection against viral infection | |
Boudet et al. | Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120 | |
AU2800392A (en) | Induction of protection against viral infection by synergy between viral proteins and viral peptides | |
Sheppard | Inactivated-or killed-virus HIV/AIDS vaccines | |
Girard et al. | Progress in the development of HIV vaccines | |
CA2538840C (fr) | Compositions issues d'un vaccin adn et leurs procedes d'utilisation | |
Bolognesi | The immune response to HIV: implications for vaccine development | |
Oxford et al. | Challenges and strategies for AIDS vaccine development | |
US20170107260A1 (en) | Mosaic hiv-1 sequences and uses thereof | |
Emini et al. | Human immunodeficiency virus | |
Cranage et al. | The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine | |
Petry et al. | Prechallenge high neutralizing antibodies and long-lasting immune reactivity to gp41 correlate with protection of rhesus monkeys against productive simian immunodeficiency virus infection or disease development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |